Summary
Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that offers development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. Its product candidates are intended for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer, non hodgkin lymphoma, and others. Erytech’s pipeline products comprise eryasp, erymet, erymmune, and others. The company also develops other product candidates which uses encapsulated enzymes to induce tumor starvation. Erytech is headquartered in Lyon, France.
Erytech Pharma SA (ERYP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Erytech Pharma Raises USD3.95 Million in Venture Financing 12
Erytech Pharma Secures USD19.24 Million in Venture Funding 13
Partnerships 14
Erytech Pharma Enters into Research Agreement with Queen’s University 14
Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 15
Invetech Enters into Agreement with Erytech Pharma 16
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa 17
Licensing Agreements 18
Erytech Pharma Enters Into Licensing Agreement With Orphan Europe For Graspa 18
Equity Offering 19
Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 19
Erytech Pharma Raises USD11 Million in Private Placement of Shares 21
Erytech Pharma Raises USD27 Million in Private Placement of Shares 22
Erytech Pharma Plans to Raise Funds through Public Offering of Shares 24
Erytech Pharma Raises USD38 Million in Private Placement of Shares 25
Erytech Pharma Completes IPO For US$21 Million 26
Erytech Pharma SA - Key Competitors 28
Erytech Pharma SA - Key Employees 29
Erytech Pharma SA - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
May 18, 2017: ERYTECH Provides Business Update and Financial Highlights For Q1 2017 31
Nov 03, 2016: ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016 33
Sep 06, 2016: ERYTECH Reports Business and Financial Update for the First Half of 2016 34
May 10, 2016: ERYTECH Provides Business and Financial Highlights for First Quarter 2016 35
Feb 23, 2016: ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015 36
Jan 11, 2016: ERYTECH Reports Financial Highlights for Q4 2015 39
Corporate Communications 40
Oct 27, 2016: Erytech Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer 40
Sep 05, 2016: Erytech Appoints Allene M. Diaz To Its Board Of Directors 41
Clinical Trials 42
Mar 20, 2017: ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017 42
Jan 17, 2017: ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium 44
Aug 29, 2016: ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA) in Acute Myeloid Leukemia 45
Jan 06, 2016: ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
Erytech Pharma SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Erytech Pharma SA, Deals By Therapy Area, 2011 to YTD 2017 9
Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Erytech Pharma Raises USD3.95 Million in Venture Financing 12
Erytech Pharma Secures USD19.24 Million in Venture Funding 13
Erytech Pharma Enters into Research Agreement with Queen’s University 14
Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 15
Invetech Enters into Agreement with Erytech Pharma 16
ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa 17
Erytech Pharma Enters Into Licensing Agreement With Orphan Europe For Graspa 18
Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 19
Erytech Pharma Raises USD11 Million in Private Placement of Shares 21
Erytech Pharma Raises USD27 Million in Private Placement of Shares 22
Erytech Pharma Plans to Raise Funds through Public Offering of Shares 24
Erytech Pharma Raises USD38 Million in Private Placement of Shares 25
Erytech Pharma Completes IPO For US$21 Million 26
Erytech Pharma SA, Key Competitors 28
Erytech Pharma SA, Key Employees 29
Erytech Pharma SA, Subsidiaries 30
List of Figures
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10
